<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033172</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2018M-042</org_study_id>
    <nct_id>NCT04033172</nct_id>
  </id_info>
  <brief_title>Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )</brief_title>
  <acronym>Pyrotinib</acronym>
  <official_title>Pyrotinib Plus Fulvestrant in Patients HR+/HER2+ Metastatic Breast Cancer : a Prospective, Single-arm, Single-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 and HER4 receptors.
      This study is a single-arm, prospective, single-center clinical study of pyrotinib plus
      fulvestrant as the therapy HR+/HER2+ metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Estimated up to 1 year</time_frame>
    <description>Defined as the time from the date of informed consent to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) or death from any cause, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>Estimated up to 1 year</time_frame>
    <description>Defined as the time from the date of informed consent until to the date of death, regardless of the cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Estimated up to 1 year</time_frame>
    <description>Defined as proportion of complete response and partial response according to RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pyrotinib plus Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib Plus Fulvestrant</intervention_name>
    <description>Pyrotinib: 400 mg/d, q.d., p.o. A course of treatment need 28 days. Fulvestrant: 500 mg/m2 q.d. i.m. A course of treatment need 28 day. First course needs extra dose of fulvestrant 500 mg/m2 q.d. i.m. on day 15.</description>
    <arm_group_label>Pyrotinib plus Fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged 18-75 years old; HR positive and HER2 positive (immunohistochemistry or
             FISH test confirmed).

          2. ECOG score ≤ 2, expected survival ≥ 3 months.

          3. Histology or cytology confirmed as breast cancer.

          4. Prior to trastuzumab and endocrine therapy and progression/recurrence.

          5. At least one RECIST 1.1 defined measurable lesions.

          6. Normal function of major organs.

        Exclusion Criteria:

          1. pregnant or lactating women

          2. Patients who have relapsed or progressed within 12 months of end of adjuvant or
             neoadjuvant therapy, including chemotherapy, target therapy (eg lapatinib，
             trastuzumab), or other anti-tumor therapy. Except for endocrine therapy.

          3. Severe chronic gastrointestinal diseases with diarrhea as the main symptom (such as
             Crohn's disease, malabsorption, or ≥2 grade diarrhea caused by any cause at baseline).

          4. Rapid progress of organ invasion (such as liver and lung disease greater than 1/2
             organ area or liver dysfunction, etc.)

          5. Patients with central nervous system disorders or mental disorders

          6. Bone metastasis lesions only, no other measurable lesions.

          7. Hypertension (systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 100
             mmHg) without ideal control.

          8. Uncontrolled heart disease.

          9. Have congenital long or short QT syndrome or have a family history or personal history
             of Brugada syndrome.

         10. Uncontrolled rain metastasis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Yuan</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian Yue</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Yuan</last_name>
    <phone>+8613501270834</phone>
    <email>yuanpeng01@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Yue</last_name>
    <phone>+8618612621749</phone>
    <email>sunlight_1985@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Yuan</last_name>
      <phone>+8613501270834</phone>
      <email>yuanpeng01@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jian Yue</last_name>
      <phone>+8618612621749</phone>
      <email>sunlight_1985@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peng Yuan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian Yue</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Peng Yuan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Metastatic Breast Cancer, Pyrotinib, Fulvestrant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

